
==== Front
Mol Ther Nucleic Acids
Mol Ther Nucleic Acids
Molecular Therapy. Nucleic Acids
2162-2531
American Society of Gene & Cell Therapy

S2162-2531(24)00199-9
10.1016/j.omtn.2024.102312
102312
Commentary
Stereopure ASOs: An unanticipated increase in selectivity for targeting mutant HTT
Gulumkar Vijay N. 1
Dowdy Steven F. sdowdy@ucsd.edu
1∗
1 Department of Cellular & Molecular Medicine, University of California, San Diego, School of Medicine, La Jolla, CA, USA
∗ Corresponding author: Steven F. Dowdy, Department of Cellular & Molecular Medicine, University of California, San Diego, School of Medicine, La Jolla, CA, USA. sdowdy@ucsd.edu
28 8 2024
10 9 2024
28 8 2024
35 3 102312© 2024 The Author(s)
2024
https://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
==== Body
pmcMain text

Huntington’s disease (HD) is a neurological genetic disorder caused by the expansion of cytosine-adenine-guanine (CAG) triplet repeats in the wild type of the Huntingtin gene (WT-HTT). The accumulation of more than 36 CAG repeats in WT-HTT leads to the formation of mutant Huntingtin (mHTT), leading to a toxic gain of function.1 In HD, mHTT protein accumulates in the brain and drives protein aggregation, transcriptional dysregulation, and dominant-negative interference with WT-HTT protein activity.2,3 While there are currently no approved disease-modifying therapies available, therapeutic approaches that reduce both WT-HTT and mHTT proteins are currently in clinical trials. Although preclinical studies indicate that a reduction of approximately 45% in WT-HTT protein can be tolerated by healthy animals (without mHTT and HD), the safety of long-term reduction of WT-HTT in patients with HD remains uncertain.4 Indeed, multiple studies have shown strong evidence that WT-HTT is neuroprotective during stress, especially in HD models.5,6 Thus, given this uncertainty, selectively reducing mtHTT, while leaving WT-HTT levels unchanged, is the preferred therapeutic approach in HD.

Based on their Watson-Crick base-pairing mechanism of action, antisense oligonucleotide (ASO) and small interfering RNA (siRNA) therapeutics have great potential to treat HD.7 Indeed, both ASOs and siRNAs that target the CAG triplet repeats have shown promise in reducing HTT levels.8,9 However, a more selective approach of targeting single-nucleotide polymorphisms (SNPs) associated with mHTT shows greater promise of differentiating between mHTT and WT-HTT.10 Bilsen et al. showed that selectively targeting an HD-associated SNP several thousand bases downstream of the CAG repeat with an siRNA selectively lowered the pathogenic allele mRNA by 80%.8 Likewise, Carroll et al. developed an ASO to SNP sites in HTT that selectively silenced mHTT.9 These allele-specific approaches enable the rapid selection of oligonucleotide therapeutics for patients with HD based on potency, selectivity, and population coverage.

ASOs typical have a full (or nearly full) phosphorothioate (PS) backbone, where one of the non-bridging oxygen atoms is replaced with a more “hydrophobic” sulfur atom that results in both a significant increase in metabolic stability and protein binding and an enhanced escape from endosomes.1,2,4 However, during synthesis, the sulfur atom is randomly placed in either the Sp or Rp stereospecific position at each internucleotide linkage, resulting in a stereomixmer of >105 stereoisomers.11 Currently, there are 7 approved stereomixmer ASOs, so clearly most, if not all, of these stereoisomers are functionally active to one extent or another. However, for more than 10 years, there has been an ongoing debate on the benefits of stereomixmer vs. stereopure ASOs12 (and this commentary is not going to resolve that argument in <600 words!).

Here, Iwamoto et al. from Wave Life Science in Cambridge, MA, adds to that debate by synthesizing a stereopure gapmer ASO (WVE-003) targeting SNP3 (rs362273) for allele-selective reduction of mHTT.13 The WVE-003 ASO also contains three stereospecific phosphoryl guanidine (PN) internucleotide linkages in the gapmer’s RNA wings. Interestingly, the results here incorporating stereopure PN modifications showed improved allele selectivity over prior molecules HTT-164 (WVE-120101) and HTT-273 (WVE-120102), which were withdrawn from the clinics due to their failure to consistently reduce mHTT levels in the cerebrospinal fluid (CSF) of patients with HD. Thus, incorporating PN modification into SNP3-targeting molecules improves their overall activity profiles. Impressively, the WVE-003 ASO showed a strong SNP3 allele-specific mHTT knockdown vs. WT-HTT or other SNP-containing mHTT alleles. Together, the stereospecific PS and PN modifications resulted in a substantial increase in selectivity, potency, durability, and delivery into cells in culture and the CNS of preclinical mouse models.

WVE-003 is also currently being evaluated in clinical trials (ClinicalTrials.gov: NCT05032196).14 As of this writing, the primary findings from the SELECT-HD study indicate that WVE-003 may reduce mHTT in patients while retaining WT-HTT activity. Therefore, an allele-selective approach that spares WT-HTT while maintaining its neuroprotective effects may be the most effective way to deliver a disease-modifying HD treatment.

Declaration of interests

The authors declare no competing interests.
==== Refs
References

1 Macdonald M. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes Cell 72 1993 971 983 10.1016/0092- 8674(93)90585-e 8458085
2 Saudou F. Humbert S. The Biology of Huntingtin Neuron 89 2016 910 926 10.1016/j.neuron.2016.02.003 26938440
3 Sturrock A. Leavitt B.R. The clinical and genetic features of Huntington disease J. Geriatr. Psychiatr. Neurol. 23 2010 243 259 10.1177/0891988710383573
4 Kordasiewicz H.B. Stanek L.M. Wancewicz E.V. Mazur C. McAlonis M.M. Pytel K.A. Artates J.W. Weiss A. Cheng S.H. Shihabuddin L.S. Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis Neuron 74 2012 1031 1044 10.1016/j.neuron.2012.05.009 22726834
5 Leavitt B.R. van Raamsdonk J.M. Shehadeh J. Fernandes H. Murphy Z. Graham R.K. Wellington C.L. Raymond L.A. Hayden M.R. Wild-type huntingtin protects neurons from excitotoxicity J. Neurochem. 96 2006 1121 1129 10.1111/j.1471-4159.2005.03605.x 16417581
6 Becanovic K. Norremolle A. Neal S.J. Kay C. Collins J.A. Arenillas D. Lilja T. Gaudenzi G. Manoharan S. Doty C.N. A SNP in the HTT promoter alters NF-kappaB binding and is a bidirectional genetic modifier of Huntington disease Nat. Neurosci. 18 2015 807 816 10.1038/nn.4014 25938884
7 Dowdy S.F. Endosomal escape of RNA therapeutics: How do we solve this rate-limiting problem? RNA 29 2023 396 401 10.1261/rna.079507.122 36669888
8 van Bilsen P.H.J. Jaspers L. Lombardi M.S. Odekerken J.C.E. Burright E.N. Kaemmerer W.F. Identification and allele-specific silencing of the mutant huntingtin allele in Huntington’s disease patient-derived fibroblasts Hum. Gene Ther. 19 2008 710 719 10.1089/HUM.2007.116 18549309
9 Carroll J.B. Warby S.C. Southwell A.L. Doty C.N. Greenlee S. Skotte N. Hung G. Bennett C.F. Freier S.M. Hayden M.R. Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Hunt-ington disease gene/allele-specific silencing of mutant huntingtin Mol. Ther. 19 2011 2178 2185 10.1038/mt.2011.201 21971427
10 Kay C. Skotte N.H. Southwell A.L. Hayden M.R. Personalized gene silencing therapeutics for Huntington disease Clin. Genet. 86 2014 29 36 10.1111/cge.12385 24646433
11 Eckstein F. Phosphorothioates, essential components of therapeutic oligonucleotides Nucleic Acid Therapeut. 24 2014 374 387 10.1089/nat.2014.0506
12 Iwamoto N. Butler D.C.D. Svrzikapa N. Mohapatra S. Zlatev I. Sah D.W.Y. Standley S.M. Standley S.M. Lu G. Apponi L.H. Control of phosphorothioate stereochemistry substantially increases the efficacy of antisense oligonucleotides Nat. Biotechnol. 35 2017 845 851 10.1038/nbt.3948 28829437
13 https://www.cell.com/molecular-therapy-family/nucleic-acids/fulltext/S2162-2531(24)00133-1.
14 https://ir.wavelifesciences.com/news-releases/news-release-details/wave-life-sciences-announces-positive-update-phase-1b2a-select.
